Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Investing.com -- Schrödinger Inc. stock fell 15% after the company announced it would discontinue development of its CDC7 inhibitor SGR-2921, which was being evaluated for certain blood cancers.
The decision follows two treatment-related deaths in the Phase 1 dose-escalation study of patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity, the company determined that the drug’s safety profile would make development as a combination therapy difficult to pursue.
"Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921," said Margaret Dugan, M.D., chief medical officer at Schrödinger.
The company had been evaluating the drug based on preclinical data showing CDC7 inhibition produced anti-leukemic responses in patient-derived AML models, suggesting potential for combination therapy with standard treatments.
The discontinuation represents a setback in Schrödinger’s clinical pipeline for addressing AML, a disease characterized by high relapse rates, rapid progression, and limited available therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.